youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
HIMS:NYSE
Hims & Hers Health Inc
$23.19
arrow_downward
-13.02%(-3.47) 1D
Nov 5, 10:56:54 AM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HIMS...
Open
$26.25
High
$26.57
Low
$22.90
Mkt. cap
5.39B
Avg. vol.
9.90M
Volume
5.26M
52-wk high
$44.00
52-wk low
$13.74
EPS
-$0.63
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
Open
$26.25
High
$26.57
Low
$22.90
Mkt. cap
5.39B
Avg. vol.
9.90M
Volume
5.26M
52-wk high
$44.00
52-wk low
$13.74
EPS
-$0.63
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Canada
·
1 hour ago
Hims & Hers adds four partners to benefits program By Investing.com
Yahoo! Finance Canada
·
2 hours ago
Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most
Zacks
·
3 hours ago
Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates
Traders Union
·
7 hours ago
Hims & Hers Health stock tests $26.9 resistance amid mixed technical signals
Profile
Hims & Hers Health, Inc., doing business as hims, is an American telehealth company headquartered in San Francisco. It provides prescription medications, over-the-counter medications, and personal care products through a direct-to-consumer subscription model. Wikipedia
About Hims & Hers Health Inc
CEO-
Employees2.44K
FoundedNov 2017
HeadquartersSan Francisco, California, United States
SectorHealth care provider
Industry-
Website-
Analyst ratings
Based on 14 analysts giving stock ratings to HIMS in the past 3 months
Hold
Buy
3
Hold
11
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for HIMS in the last 3 months.
Highest
Current $23.19
$42.00 (+81.11%)
Average
$32.82 (+41.53%)
Lowest
$26.00 (+12.12%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Allen Lutz Bank of America Securities | Hold | Maintained | $32.00 | +38% | 10/28/2026 |
Glen Santangelo Barclays | Buy | Maintained | $35.00 | +50.9% | 10/29/2026 |
Jailendra Singh Truist Financial | Hold | Reiterated | $32.00 | +38% | 09/11/2026 |
Bryan Smilek J.P. Morgan | Hold | Initiated | $32.00 | +38% | 09/11/2026 |
Brian Tanquilut Jefferies | Hold | Maintained | $31.00 | +33.7% | 09/03/2026 |
Justin Patterson KeyBanc | Hold | Maintained | - | - | 09/02/2026 |
George Hill Deutsche Bank | Hold | Reiterated | $26.00 | +12.1% | 08/11/2026 |
Jonna Kim TD Cowen | Hold | Reiterated | $30.00 | +29.4% | 08/11/2026 |
Craig Hettenbach Morgan Stanley | Hold | Reiterated | $28.00 | +20.7% | 08/11/2026 |
Maria Ripps Canaccord Genuity | Buy | Reiterated | $40.00 | +72.5% | 08/11/2026 |
Ryan MacDonald Needham | Buy | Reiterated | $42.00 | +81.1% | 08/11/2026 |
David Larsen BTIG | Hold | Reiterated | - | - | 08/11/2026 |
Daniel Grosslight Citi | Hold | Maintained | $33.00 | +42.3% | 08/12/2026 |
Mark Mahaney Evercore ISI | Hold | Maintained | - | - | 08/11/2026 |
Oliver Chen TD Cowen | Hold | Reiterated | $25.00 | +7.8% | 05/12/2026 |
Cory Carpenter J.P. Morgan | Buy | Maintained | $33.00 | +42.3% | 05/12/2026 |
Michael Cherny Leerink Partners | Hold | Maintained | - | - | 04/16/2026 |
Unknown Analyst Nephron | Buy | Upgraded | $35.00 | +50.9% | 03/09/2026 |
Next call in 4 days
Tue, Nov 10, 12:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.15
Revenue / Est. (USD)
- / 892.77M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 598.98M | 617.82M | 608.10M | 753.21M |
Cost of goods sold | 156.92M | 173.38M | 182.82M | 272.41M |
Cost of revenue | 156.92M | 173.38M | 182.82M | 272.41M |
Research and development expenses | 40.58M | 40.96M | 46.94M | 54.90M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 389.67M | 386.64M | 426.37M | 521.95M |
Operating expense | 430.25M | 427.60M | 473.31M | 576.85M |
Total operating expenses | 587.17M | 600.99M | 656.13M | 849.26M |
Operating income | 11.81M | 16.83M | -48.02M | -96.04M |
Other non operating income | -5.99M | -575.00K | -18.58M | -2.43M |
EBT including unusual items | 12.22M | 18.35M | -101.55M | -92.63M |
EBT excluding unusual items | 12.22M | 21.56M | -61.57M | -96.22M |
Income tax expense | -3.55M | -2.25M | -9.44M | -6.34M |
Effective tax rate | -29.05% | -12.25% | 9.29% | 6.85% |
Other operating expenses | - | - | - | - |
Net income | 15.77M | 20.60M | -92.12M | -86.29M |
Net profit margin | 2.63% | 3.33% | -15.15% | -11.46% |
Earnings per share | 0.28 | 0.22 | -0.19 | -0.09 |
Interest and investment income | 8.01M | 6.80M | 7.90M | 6.00M |
Interest expense | -1.60M | -1.50M | -2.87M | -3.75M |
Net interest expenses | 6.41M | 5.30M | 5.03M | 2.25M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 29.48M | 34.92M | -26.07M | -66.57M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events